![]() |
市場調査レポート
商品コード
342571
心房細動 (AF) の予測:主要19市場Epiomic Epidemiology Series: Atrial Fibrillation Forecast in 19 Major Markets 2020-2030 |
心房細動 (AF) の予測:主要19市場 |
出版日: 2020年03月20日
発行: Black Swan Analysis
ページ情報: 英文 76 Pages
納期: 即納可能
![]() |
心房細動 (AF) は、上室性不整脈の最も一般的なタイプです。異常な電気信号が心房に送られると、心房細動 (AF) が引き起こされます。
当レポートでは、主要19市場 (米国、カナダ、フランス、ドイツ、イタリア、スペイン、英国、ポーランド、オランダ、ロシア、トルコ、日本、中国、韓国、インド、オーストラリア、ブラジル、メキシコ、アルゼンチン) における心房細動 (AF) の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、疾患の概要、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Atrial Fibrillation in 19 Major Markets.
Atrial Fibrillation (AF) is the most prevalent type of supraventricular arrhythmia. AF occurs when abnormal electric signals are sent to the atria, which cause them to contract quickly and irregularly. For many patients, the condition is largely asymptomatic, however when symptoms become bothersome and frequent, intervention is required to restore normal rhythm.
This report provides the current prevalent population for AF across 19 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the classification and patient treatment options for AF. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main patient features and co-morbidities of AF have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.